A collaborative project started by a team of surgeons and researchers

The tool that is being developed by SurgiMab was originally imagined for oncology surgeons, with the aim to bring to the OR a peroperative diagnosis tool that can be used in real time, during surgery. This tool is based on the use of a manual optical device hold by the surgeon, together with an injectable fluorescent conjugate that will specifically recognize and target tumor cells.

The original research project was started within Montpellier Cancer Research Institute (IRCM), within Dr. André Pélegrin’s lab.

The Parisian company Synth-Innove is our partner for the development of a fluorescent dye aproved in the clinic for peroperative applications.

Since may 2012, SurgiMab has been working with the team of Leads to Developments (L2D) who will actively participate to the optimization of its pre-clinical and clinical development plans, with a special focus on regulatory issues. L2D will also be in charge of preparing the IMPD file that will be included in SurgiMab’s phase I clinical trial application.

Montpellier Métropole’s BIC (Business and Innovation Centre), the Languedoc-Roussillon region and Transferts-LR have participated to the development of the project.

BPI France participated to the funding of the company, by awarding the company a total of 500 k€ of aids since creation.

One of the major assets of the company relies in the involvement of surgical teams in the projet from the early beginning. The appropriation of the technolgy by the surgeons was optimized in order to allow an easy and quick examination of the fluorescence during surgery. Integrating the team within the Regional anti Cancer Center in Montpellier (ICM) initially allowed everyday discussions and collaborations with the MDs involved in the project. Alex Vahrmeijer’s “Image Guided Surgery lab” at LUMC then became a priviledged partner of SurgiMab, first participating to pre-clinical studies, then leading our Phase II and III clinical studies. With 10 clinical centers currently involved in the Phase III clinical trial, and others to come, this involvement of surgeons is more than ever of extreme importance to SurgiMab.